Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Uridine 5'-Triphosphate (UTP) Solution for Inhalation
Uridine 5'-Triphosphate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Uridine 5'-Triphosphate (UTP) Solution for Inhalation | DRUG | - |
Inclusion Criteria: * be suspected of having primary lung cancer based upon chest radiograph(s), CT scan(s), or PET scan(s) and with symptom, risk profile, or history suggestive of malignancy * have FEV1 greater than or equal to 40% predicted normal for age and height Exclusion Criteria: * have o...
Top 20 of 75 competitors
Uridine 5'-Triphosphate is being studied for lung cancer. It is an investigational small molecule developed by Merck & Company, Inc. (MRK) and has reached Phase 3 clinical development. It is not described as an approved therapy, and its only recorded trial in lung cancer has been completed.
Uridine 5'-Triphosphate is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor associated with the Phase 3 program for this small molecule in lung cancer.
Uridine 5'-Triphosphate is in Phase 3 development for lung cancer. One Phase 3 trial has been completed, and no trials are currently listed as active. The program is investigational and has not been described as FDA approved.
Uridine 5'-Triphosphate has been studied in one Phase 3 trial, NCT00210080, titled A Study to Diagnose Lung Cancer by Sputum Cytology (01-312). The trial enrolled 700 participants, was randomized and double blind, and its status is completed.
Yes. Uridine 5'-Triphosphate is also known as Uridine 5'-Triphosphate (UTP) Solution for Inhalation. Both names refer to the same investigational small molecule being developed by Merck & Company, Inc. (MRK) for lung cancer.